Monday, March 16, 2026 3/16/2026

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Award Number: UM1CA186709
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/13/2014
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - The NCI-designated Dana-Farber/Harvard Cancer Center (DF/HCC) includes the Dana-Farber Cancer Institute (DFCI)/Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and the Beth Israel Deaconess Medical Center (BIDMC), which together comprise a Lead Academic Organization (LAO) in the integrated NCI Experimental Therapeutics Clinical Trials Network (ETCTN). Under the auspices of a UM1 Cooperative Agreement, the DF/HCC LAO has participated in 15 NCI-CTEP project teams, with leadership roles on 6 teams, led 20 ETCTN trials and participated in 43 studies, with an average of 102 enrollments per year over the last 5 years. Our LAO utilizes a multiple PD/PI structure and includes (1) a core of translational investigators with expertise in biomarker development for signal transduction, cell cycle, DNA repair and immuno-oncology agents, as well as proficiency in liquid biopsy analyses, computational biology and beside- to-bench cell line, organoid and PDX model development; (2) investigators who conduct Phase 1 and basket studies, as well as eight lead disease-focused investigators who work with DF/HCC Program and SPORE leaders to conduct disease-specific ETCTN trials; (3) representatives of DF/HCC interventional radiology, research pathology and biostatistics; and (4) leaders who direct regulatory oversight and a robust mentoring program for early career clinical and translational investigators. Through continued participation in NCI Project Teams and the leveraging of DF/HCC translational science, DF/HCC investigators will develop letters of intent and statistically rigorous protocols utilizing CTEP IND agents as monotherapies or in rational combinations that will be efficiently conducted and reported in collaboration with other ETCTN sites. Additionally, our investigators will accrue to ETCTN studies led by other LAOs with the overall goal of at least 30% network participation and 100 enrollments per year. Investigators will utilize both DF/HCC cores and NCI central laboratories to incorporate validated integral and integrated biomarker assays and exploratory biomarkers in trial designs that examine proof-of-principle evidence of therapeutic activity in selected patient populations, proof-of-mechanism evidence of target engagement, as well as signatures of response, pathway adaptation and resistance. The DF/HCC LAO will maintain extensive commitments to the training of early career investigators in developmental therapeutics and to strategic initiatives to extend ETCTN trials across our catchment area.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	001	9	2/27/2026	NON-COMPETING CONTINUATION	$0
2026	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	000	9	2/24/2026	NON-COMPETING CONTINUATION	$0
2026	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	002	9	2/27/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $2,268,254 )
2025	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	003	9	9/19/2025	SUPPLEMENT FOR EXPANSION	$194,240
2025	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	002	9	6/2/2025	NON-COMPETING CONTINUATION	$207,400
2025	2025	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	001	9	3/20/2025	NON-COMPETING CONTINUATION	$1,866,614
2025	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	000	8	3/19/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,268,254

Issue Date FY: 2024 ( Subtotal = $1,970,313 )
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	007	8	4/15/2024	NON-COMPETING CONTINUATION	$1,970,313
2024	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	004	7	11/7/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	006	7	4/12/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	005	7	12/7/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	003	7	10/27/2023	EXTENSION WITH OR WITHOUT FUNDS	$811,951
2024	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	6	10/27/2023	SUPPLEMENT FOR EXPANSION	-$124,999
2024	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	002	6	10/27/2023	SUPPLEMENT FOR EXPANSION	-$100,000
2024	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	000	6	10/27/2023	COMPETING CONTINUATION	-$586,952
														Subtotal = $1,970,313

Issue Date FY: 2023 ( Subtotal = $2,555,380 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	002	7	9/21/2023	EXTENSION WITH OR WITHOUT FUNDS	$522,846
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Treatment Research	001	7	8/11/2023	EXTENSION WITH OR WITHOUT FUNDS	$405,832
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	000	7	7/20/2023	EXTENSION WITH OR WITHOUT FUNDS	$1,626,702
														Subtotal = $2,555,380

Issue Date FY: 2021 ( Subtotal = $224,919 )
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	002	6	7/28/2021	SUPPLEMENT FOR EXPANSION	$124,999
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	6	6/3/2021	SUPPLEMENT FOR EXPANSION	$100,000
2021	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	000	6	4/29/2021	COMPETING CONTINUATION	-$80
														Subtotal = $224,919

Issue Date FY: 2020 ( Subtotal = $6,942,492 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	004	6	8/10/2020	COMPETING CONTINUATION	$0
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	003	6	7/29/2020	COMPETING CONTINUATION	$873,200
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	001	6	7/27/2020	COMPETING CONTINUATION	$591,900
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	000	6	4/29/2020	COMPETING CONTINUATION	$6,279,792
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	005	6	8/11/2020	COMPETING CONTINUATION	$70,800
2020	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	002	5	7/29/2020	NON-COMPETING CONTINUATION	-$873,200
														Subtotal = $6,942,492

Issue Date FY: 2019 ( Subtotal = $2,325,303 )
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	001	5	3/1/2019	NON-COMPETING CONTINUATION	$1,516,251
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	002	5	4/9/2019	NON-COMPETING CONTINUATION	$218,073
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	003	5	6/12/2019	NON-COMPETING CONTINUATION	$590,979
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	004	5	9/19/2019	NON-COMPETING CONTINUATION	$0
2019	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	000	4	2/5/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,325,303

Issue Date FY: 2018 ( Subtotal = $1,952,701 )
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	000	4	3/1/2018	NON-COMPETING CONTINUATION	$765,002
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	005	4	8/29/2018	NON-COMPETING CONTINUATION	$196,370
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	001	4	3/9/2018	NON-COMPETING CONTINUATION	$641,830
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	007	4	9/10/2018	NON-COMPETING CONTINUATION	$0
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	006	4	9/3/2018	NON-COMPETING CONTINUATION	$97,887
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	004	4	8/27/2018	NON-COMPETING CONTINUATION	$98,450
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	003	4	8/20/2018	NON-COMPETING CONTINUATION	$25,300
2018	2018	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	002	4	8/8/2018	NON-COMPETING CONTINUATION	$127,862
														Subtotal = $1,952,701

Issue Date FY: 2017 ( Subtotal = $0 ) (Continued on the next page)
2017	2016	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Treatment Research	001	3	2/28/2017	SUPPLEMENT FOR EXPANSION	$0
Grand Total All Awards = $23,631,028

Page 1 of 2 (64 items)12

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Award Number: UM1CA186709

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/13/2014

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer